Reference
Osawa H. Efficacy and safety of SOX as an adjuvant therapy for stage 2/3 colon cancer in a group at high risk of recurrence in prospective study. Annals of Oncology 27 (Suppl. 9): ix64-ix65 abstr. 209P, 20 Dec 2016. Available from: URL: http://doi.org/10.1093/annonc/mdw581.042[abstract] - Japan
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1679, 24 (2017). https://doi.org/10.1007/s40278-017-38749-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-38749-9